Citations

Showing 10 of 108119 citations.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, Michael , Dueck, Amylou C. , Frantal, Sophie, Martín, Miguel , Burstein, H.J., Greil, Richard , Fox, Peter , Wolff, Antonio C. , Chan, Arlene , Winer, Eric P. , Pfeiler, Georg , Miller, Kathy D. , Suga, Jennifer M. , Rubovsky, Gabor, Bliss, Judith M. , Nowecki, Zbigniew , Hahn, Olwen, Thomson, Jacqui, Amillano, Kepa , Rugo, Hope S. , Steger, Guenther G. , Aranguiz, Blanca Hernando Fernández de , Haddad, Tufia C. , Perelló, Antonia , Bellet, Meritxell , Fohler, Hannes, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline , Theall, K. P., Lu, Dongrui R. , Tenner, Kathleen , Fesl, Christian , investigators, on behalf of the PALLAS groups and, Colleoni, Marco , Rubovsky, Gabor , Mayer, IA , Singer, Christian F , Nowecki, Zbigniew , Thomson, Jacqui , Rugo, Hope S , Hernando Fernández de Aránguiz, Blanca , Haddad, Tufia C , Metzger Filho, Otto , Schurmans, Céline , Lu, Dongrui R , Fesl, Christian , DeMichele, Angela , Mayer, Erica L , Dueck, A. C. , Wolff, Antonio C , Winer, Eric , Martin, Miguel , Gnant, Michael , Miller, Kathy D , Bliss, Judith , Colleoni, Marco , Mayer, Ingrid A. , Singer, Christian F. , Wolmark, Norman , Metzger, Otto , DeMichele, Angela , Mayer, Erica L. , investigators, on behalf of the PALLAS groups and

Mayo Clinic

Journal of Clinical Oncology | December 7, 2021 | Volume: 40 | Issue: 3 | Pages: 282-293

10.1200/jco.21.02554 | PMID 34874182 Get It

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.
Characterising suicide-related self-disclosure by peer specialists: a qualitative analysis of audio-recorded sessions
Klim, Casimir , Vitous, C. Ann , Keller‐Cohen, Deborah, Vega, Eduardo, Forman, Jane , Lapidos, Adrienne , Pfeiffer, Paul N., Abraham, Kristen M. , Pfeiffer, Paul N.

Mayo Clinic

Advances in Mental Health | December 7, 2021 | Volume: 20 | Issue: 2 | Pages: 170-180

10.1080/18387357.2021.2010585 | PMID 35756076 Get It

Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C
Stämmler, Frank , Grassi, M , Meeusen, Jeffrey W. , Lieske, John C. , Dasari, Surendra , Dubourg, Laurence , Ehrich, J. H. H. , Schiffer, Eric, Lieske, John C , Grassi, Marcello , Lemoine, Sandrine

Mayo Clinic

Diagnostics | December 7, 2021 | Volume: 11 | Issue: 12 | Pages: 2291

10.3390/diagnostics11122291 | PMID 34943527 Get It

Assessment of renal function relies on the estimation of the glomerular filtration rate (eGFR). Existing eGFR equations, usually based on serum levels of creatinine and/or cystatin C, are not uniformly accurate across patient populations. In the present study, we expanded a recent proof-of-concept approach to optimize an eGFR equation targeting the adult population with and without chronic kidney disease (CKD), based on a nuclear magnetic resonance spectroscopy (NMR) derived ‘metabolite constellation’ (GFRNMR). A total of 1855 serum samples were partitioned into development, internal validation and external validation datasets. The new GFRNMR equation used serum myo-inositol, valine, creatinine and cystatin C plus age and sex. GFRNMR had a lower bias to tracer measured GFR (mGFR) than existing eGFR equations, with a median bias (95% confidence interval [CI]) of 0.0 (−1.0; 1.0) mL/min/1.73 m2 for GFRNMR vs. −6.0 (−7.0; −5.0) mL/min/1.73 m2 for the Chronic Kidney Disease Epidemiology Collaboration equation that combines creatinine and cystatin C (CKD-EPI2012) (p < 0.0001). Accuracy (95% CI) within 15% of mGFR (1-P15) was 38.8% (34.3; 42.5) for GFRNMR vs. 47.3% (43.2; 51.5) for CKD-EPI2012 (p < 0.010). Thus, GFRNMR holds promise as an alternative way to assess eGFR with superior accuracy in adult patients with and without CKD.
Response to: Invasive Treatments for Low Back Disorders and the ACOEM Practice Guidelines
Sayeed, Yusef, Chang, Richard G., Chhatre, Akhil, Vallabh, Jayesh, Soin, Amol, Mauck, William D., Duszynski, Belinda S., Kreiner, D. Scott, Sayeed, Yusef, Chang, Richard G., Chhatre, Akhil, Vallabh, Jayesh, Soin, Amol, Mauck, William D., Duszynski, Belinda S., Kreiner, D. Scott

Mayo Clinic

Journal of Occupational & Environmental Medicine | December 7, 2021 | Volume: 64 | Issue: 2 | Pages: e81-e83

10.1097/jom.0000000000002454 | PMID 34873134 Get It

Assessment of diastolic function in aortic stenosis: A comparison between 2009 and 2016 guidelines
Carter‐Storch, Rasmus , Mogensen, Nils Sofus Borg , Ali, Mulham , Laursen, K , Mortensen, Nils Sofus Borg , Carter-Storch, Rasmus , Pellikka, Patricia A. , Møller, Jacob Eifer , Dahl, Jordi S.

Mayo Clinic

Echocardiography | December 7, 2021 | Volume: 38 | Issue: 12 | Pages: 2006-2015

10.1111/echo.15230 | PMID 34921437 Get It

AbstractAimsNew diastolic dysfunction (DD) guidelines were introduced in 2016 to replace the 2009 guidelines, but have not yet been evaluated in aortic stenosis (AS). We aimed to compare the 2009 and 2016 DD guidelines in severe AS patients in terms of association with left ventricular (LV) and left atrial (LA) remodeling, with pulmonary capillary wedge pressure (PCWP) at rest and exercise, and with prognosis.Methods and resultsWe included 212 patients with severe AS (112 undergoing AVR, 100 asymptomatic). Echocardiography, magnetic resonance imaging, and brain natriuretic peptides (BNP) were performed/measured. Thirty‐nine asymptomatic patients had PCWP measured during rest and maximal exertion. Asymptomatic patients were followed for 3.1 years for the combined endpoint of death, AVR or admission with heart failure. The 2009 and 2016 DD guidelines agreed poorly with each other (Cohens’ κ = .15). 2009 guidelines showed many ambiguous DD findings. With the 2016 guidelines, 20% of patients had indeterminate DD. DD grade 2 according to 2016 guidelines showed stronger association with symptom status, BNP, global longitudinal strain (GLS) and peak exercise PCWP than 2009 guidelines. For indeterminate DD patients according to 2009 guidelines, GLS above the median was associated with event‐free survival (HR .11 (95% CI .02–.53)). For neither guideline was DD associated with the combined endpoint in asymptomatic patients.ConclusionThe 2016 guidelines show a stronger association with BNP, GLS, and exercise PCWP than the 2009 guidelines. The 2016 guidelines result in 20% of patients with indeterminate DD; however, these patients may possibly be stratified according to GLS.
miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy
Pottoo, Faheem Hyder , Iqubal, Ashif , Rahman, Jawad Ur , Alhajri, Noora , Shehadeh, Mustafa, Rahman, Jawad Ur , AlHajri, Noora , Iqubal, Mohammad Kashif , Salahuddin, Mohammed

Mayo Clinic

Cancers | December 7, 2021 | Volume: 13 | Issue: 23 | Pages: 6145

10.3390/cancers13236145 | PMID 34885253 Get It

In the last few decades, carcinogenesis has been extensively explored and substantial research has identified immunogenic involvement in various types of cancers. As a result, immune checkpoint blockers and other immune-based therapies were developed as novel immunotherapeutic strategies. However, despite being a promising therapeutic option, immunotherapy has significant constraints such as a high cost of treatment, unpredictable toxicity, and clinical outcomes. miRNAs are non-coding, small RNAs actively involved in modulating the immune system’s multiple signalling pathways by binding to the 3′-UTR of target genes. miRNAs possess a unique advantage in modulating multiple targets of either the same or different signalling pathways. Therefore, miRNA follows a ‘one drug multiple target’ hypothesis. Attempts are made to explore the therapeutic promise of miRNAs in cancer so that it can be transported from bench to bedside for successful immunotherapeutic results. Therefore, in the current manuscript, we discussed, in detail, the mechanism and role of miRNAs in different types of cancers relating to the immune system, its diagnostic and therapeutic aspect, the effect on immune escape, immune-checkpoint molecules, and the tumour microenvironment. We have also discussed the existing limitations, clinical success and the prospective use of miRNAs in cancer.
Untangling senescent and damage‐associated microglia in the aging and diseased brain
Ng, Pei Ying , McNeely, Taylor , Baker, Darren J. , Ng, Pei Y , McNeely, Taylor L , Baker, Darren J

Mayo Clinic

The FEBS Journal | December 7, 2021 | Volume: 290 | Issue: 5 | Pages: 1326-1339

10.1111/febs.16315 | PMID 34873840 Get It

Microglial homeostasis has emerged as a critical mediator of health and disease in the central nervous system. In their neuroprotective role as the predominant immune cells of the brain, microglia surveil the microenvironment for debris and pathogens, while also promoting neurogenesis and performing maintenance on synapses. Chronological ageing, disease onset, or traumatic injury promotes irreparable damage or deregulated signaling to reinforce neurotoxic phenotypes in microglia. These insults may include cellular senescence, a stable growth arrest often accompanied by the production of a distinctive pro‐inflammatory secretory phenotype, which may contribute to age‐ or disease‐driven decline in neuronal health and cognition and is a potential novel therapeutic target. Despite this increased scrutiny, unanswered questions remain about what distinguishes senescent microglia and non‐senescent microglia reacting to insults occurring in ageing, disease, and injury, and how central the development of senescence is in their pivot from guardian to assailant. To intelligently design future studies to untangle senescent microglia from other primed and reactionary states, specific criteria must be developed that define this population and allow for comparisons between different model systems. Comparing microglial activity seen in homeostasis, ageing, disease, and injury allows for a more coherent understanding of when and how senescent and other harmful microglial subpopulations should be targeted.
Recommendations From the Society for the Advancement of Transplant Anesthesiology Fellowship Committee: Core Competencies and Milestones for the Kidney/Pancreas Component of Abdominal Organ Transplant Anesthesia Fellowship
Souki, Fouad G. , Chadha, Ryan , Planinsic, Raymond M. , Zerillo, Jeron , Nguyen, Christine , Smith, Natalie , Mandell, M. Susan , Sakai, Tetsuro , Nicolau‐Raducu, Ramona , Chadha, Ryan , Nguyen-Buckley, Christine

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | December 7, 2021 | Volume: 26 | Issue: 1 | Pages: 15-26

10.1177/10892532211058574 | PMID 34872395 Get It

The Society for the Advancement of Transplant Anesthesia (SATA) is dedicated to improving patient care in all facets of transplant anesthesia. The anesthesia fellowship training recommendations for thoracic transplantation (heart and lungs) and part of the abdominal organ transplantation (liver) have been presented in previous publications. The SATA Fellowship Committee has completed the remaining component of abdominal transplant anesthesia (kidney/pancreas) and has assembled core competencies and milestones derived from expert consensus to guide the education and overall preparation of trainees providing care for kidney/pancreas transplant recipients. These recommendations provide a comprehensive approach to pre-operative evaluation, vascular access procedures, advanced hemodynamic monitoring, assessment of coagulation and metabolic abnormalities, operative techniques, and post-operative pain control. As such, this document supplements the current liver/hepatic transplant anesthesia fellowship training programs to include all aspects of “Abdominal Organ Transplant Anesthesia” recommended knowledge.
COVID-19 Care Clinic in a Medical Center: Lessons Learned
Tulledge‐Scheitel, Sidna M. , Billings, Thomas A., Homme, Jason H. , Miller, Jennifer , North, Frederick , Sanderson, Rachael L. , Schroeder, Darrell R. , Vaughan, Marvin A., Croghan, Ivana T. , Miller, Jennifer M, Sanderson, Rachael L , Croghan, Ivana T , Schroeder, Darrell , Billings, Thomas A., Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | December 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211056796 | PMID 34872410 Get It

Objective: The purpose of this report is to describe the elements of a Covid-19 Care Clinic (CCC), patient demographics, and outcomes. Methods: Descriptive statistics were used to describe demographics, clinical characteristics, and outcomes. This report is based on 4934 unique patients seen in the CCC who provided research authorization within a 10-month period of time (April 1, 2020-January 31, 2021). The CCC infection control processes consisted of a rooming process that mitigated SARS-COV-2 transmission, preparing examination rooms, using PPE by staff, in room lab drawing, and escorting services to minimize the time in clinic. Results: Of the 4934 unique patients seen (age range newborn-102 years), 76.8% were tested for COVID-19. Of those tested, 11.8% were positive for SARS-CoV-2. Ninety-two percent of the patients with the reason for the visit documented had COVID-19 type symptoms. Cough, shortness of breath, and chest pain were the most common presenting symptom in those with COVID-19. At the time of the visit in the CCC, 5.8% of the patients were actively contagious. Thirty days after being seen in the CCC, 9.1% of the patients were seen in the emergency department (ED) and 0.2% died. During the 10-month period there were no known occupationally related COVID-19 infections. Conclusion: The COVID-19 Care Clinic provided face-to-face access for all ages with COVID-19 type symptoms. A minority of patients had COVID-19 who were seen in the clinic. The clinic provided an additional venue of care outside of the ED. The infectious control measures employed were highly effective in protecting the staff. Lessons learned allow for decentralization of COVID-19 symptom care to the primary care practices employing the infection control measures.